Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701675 | 1.00 | CYP19A1 (0.54) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL6570371 | 1.00 | CYP19A1 (0.54) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL835059 | 0.84 | IDO1 (0.47) | CYP19A1GBA1PLAUSIGMAR1 | |
| SCHEMBL29447948 | 0.84 | IDO1 (0.47) | CYP19A1GBA1PLAUSIGMAR1 | |
| SCHEMBL9567953 | 0.84 | GBA1 (0.55) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL11069425 | 0.82 | CYP19A1 (0.50) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL12422869 | 0.82 | ADRA1D (0.58) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL9568087 | 0.81 | GBA1 (0.59) | CYP19A1GBA1PLAUHTR1ASIGMAR1 | |
| SCHEMBL17060555 | 0.79 | DGAT1 (0.56) | — | |
| SCHEMBL6427588 | 0.79 | CYP19A1 (0.54) | CYP19A1GBA1PLAUHTR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| CN-114174263-B | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-110997661-B | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-07 | — | — | US | disclosed |
| EP-3966199-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2022-03-16 | — | — | EP | disclosed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3634958-B1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3183242-B1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-0138441-B1 | ANTICONVULSANT SULFAMATE DERIVATIVES | McNeilab, Inc. (US) | 1988-08-03 | — | — | EP | disclosed |
| US-4705871-A | Aralkoxy and aryloxyalkoxy kojic acid derivatives | G. D. SEARLE & CO. (US) | 1987-11-10 | — | — | US | disclosed |
| US-4644071-A | Aralkoxy and aryloxyalkoxy kojic acid derivatives | G. D. SEARLE & CO. (US) | 1987-02-17 | — | — | US | disclosed |
| US-4625034-A | 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives | USV PHARMACEUTICAL CORP. (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0190722-A2 | Dihydro and tetrahydroquinoline derivatives | USV PHARMACEUTICAL CORPORATION (US) | 1986-08-13 | — | — | EP | disclosed |
| US-4582916-A | CHEMICAL INTERMEDIATES FOR ANTICONVULSANT AGENTS | MCNEILAB, INC. (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0138441-A2 | Anticonvulsant sulfamate derivatives | McNeilab, Inc. (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4513006-A | ANTIEPILEPTIC AGENTS; ANTIGLAUCOMA AGENTS | MCNEIL LAB., INC. (US) | 1985-04-23 | — | — | US | disclosed |
| US-4276305-A | INSECTICIDES, MITICIDES | HOFFMANN-LA ROCHE INC. (US) | 1981-06-30 | — | — | US | disclosed |
| EP-0014455-A2 | Cyclopropane(thiol)carboxylic-acid esters, processes for their preparation, pesticides containing such compounds and the use of such compounds as pesticides | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | CYP19A1 4315/4885GBA1 4153/4885PLAU 661/4885 |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | CYP19A1 4444/4885GBA1 1/4885PLAU 636/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | CYP19A1 4546/4885GBA1 1/4885PLAU 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.